<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289990</url>
  </required_header>
  <id_info>
    <org_study_id>1245.31</org_study_id>
    <secondary_id>2010-022718-17</secondary_id>
    <nct_id>NCT01289990</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy and long term safety and tolerability of BI 10773 in
      type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in HbA1c after 52 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment</measure>
    <time_frame>Baseline and 76 weeks</time_frame>
    <description>Change from baseline in HbA1c after 76 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c (%) Changes From Baseline After 76 Weeks of Treatment</measure>
    <time_frame>Baseline and 76 weeks</time_frame>
    <description>Change from baseline in HbA1c (%) after 76 weeks using MMRM approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Systolic blood pressure - change from baseline after 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment</measure>
    <time_frame>Baseline and 76 weeks</time_frame>
    <description>Systolic blood pressure - change from baseline after 76 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Diastolic blood pressure - change from baseline after 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment</measure>
    <time_frame>Baseline and 76 weeks</time_frame>
    <description>Diastolic blood pressure - change from baseline after 76 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight (kg) Change From Baseline After 52 Weeks of Treatment</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Body Weight (kg) - Change From Baseline After 52 Weeks of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight (kg) Change From Baseline After 76 Weeks of Treatment</measure>
    <time_frame>Baseline and 76 weeks</time_frame>
    <description>Body Weight (kg) - Change From Baseline After 76 Weeks of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference (cm) Change From Baseline After 52 Weeks of Treatment</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Waist circumference (cm) - change from baseline after 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference (cm) Change From Baseline After 76 Weeks of Treatment</measure>
    <time_frame>Baseline and 76 weeks</time_frame>
    <description>Waist circumference (cm) - change from baseline after 76 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose Change From Baseline After 52 Weeks of Treatment</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Fasting plasma glucose - change from baseline after 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment</measure>
    <time_frame>Baseline and 76 weeks</time_frame>
    <description>Fasting plasma glucose - change from baseline after 76 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">2705</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 low (drug naive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high (drug naive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (drug naive)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BI 10773 / Sitagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100mg (drug naive)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 low (pioglitazone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high (pioglitazone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (pioglitazone)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BI 10773 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 low (metformin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high (metformin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (metformin)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BI 10773 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 low (metformin+sulfonylurea)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high (metformin+sulfonylurea)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (metformin+sulfonylurea)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BI 10773</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 low (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>Placebo (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>Sitagliptin 100mg (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching Sitagliptin</description>
    <arm_group_label>Placebo (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>BI 10773 low (metformin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>Placebo (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 high (metformin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>Placebo (pioglitazone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>Sitagliptin 100mg (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 low (pioglitazone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>Placebo (metformin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>BI 10773 low (pioglitazone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching Sitagliptin</description>
    <arm_group_label>BI 10773 high (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 low (metformin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 low (metformin+sulfonylurea)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 high (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>Placebo (metformin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 high (metformin+sulfonylurea)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>BI 10773 high (metformin+sulfonylurea)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>Placebo (pioglitazone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching Sitagliptin</description>
    <arm_group_label>BI 10773 low (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100mg</intervention_name>
    <description>Sitagliptin once daily</description>
    <arm_group_label>Sitagliptin 100mg (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily</description>
    <arm_group_label>BI 10773 high (pioglitazone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>BI 10773 high (pioglitazone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>Placebo (metformin+sulfonylurea)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>BI 10773 high (drug naive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>Placebo (metformin+sulfonylurea)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>BI 10773 high (metformin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>BI 10773 low (metformin+sulfonylurea)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>BI 10773 low (drug naive)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients completing the entire treatment period of the preceding double-blind trial
             1245.19, 1245.20 or 1245.23 with or without rescue therapy.

          2. Signed and dated written informed consent by date of Visit 1 in accordance with Good
             Clinical Practice and local legislation.

        Exclusion criteria:

          1. Patient who meet one or more of the withdrawal criteria of the treatment period of the
             previous trial 1245.19, 1245.20 or 1245.23.

          2. Indication of liver disease, defined by serum levels of either alanine
             aminotransferase , aspartate aminotransferase, or alkaline phosphatase above 3 x upper
             limit of normal as determined during last visit of preceding trial.

          3. Impaired renal function defined as glomerular filtration rate&lt;30 ml/min (severe renal
             impairment, Modification of Diet in Renal Disease formula) as determined during last
             visit of preceding trial.

          4. Contraindications to sitagliptin, pioglitazone, metformin or sulfonylurea according to
             local label, which started during trial participation in 1245.19, 1245.20 or 1245.23

          5. Pre-menopausal women (last menstruation &lt; or = 1 year prior to informed consent) who
             are nursing or pregnant or are of child-bearing potential and are not practicing an
             acceptable method of birth control, or do not plan to continue using this method
             throughout the study and do not agree to submit to periodic pregnancy testing during
             participation in the trial. Acceptable methods of birth control include tubal
             ligation, transdermal patch, intra uterine devices/systems, oral, implantable or
             injectable contraceptives, sexual abstinence (if acceptable by local authorities),
             double barrier method and vasectomised partner.

          6. Alcohol or drug abuse within the 3 months prior to informed consent that would
             interfere with trial participation or any ongoing condition leading to a decreased
             compliance to study procedures or study drug intake.

          7. Participation in another trial with an investigational drug within 30 days prior to
             informed consent (except 1245.19, 1245.20 and 1245.23).

          8. Any other clinical condition that would jeopardize patient's safety while
             participating in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.31.10145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10162 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10149 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Northglenn</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10159 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10146 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carlisle</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gallipolis</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10158 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10156 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.10155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>De Pinte</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deurne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deurne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goz√©e</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leopoldsburg</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linkebeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mouscron</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sint-Gillis-Waas</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tielt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.32026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tremelo</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paradise</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strathroy</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montague</city>
        <state>Prince Edward Island</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ville Saint-Laurent</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.20041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jingzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nan Ning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nan Ning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>QingDao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shantou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shiyan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bers√©e</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bischheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bondy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruay La Buissiere</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Croix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hautmont</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Narbonne Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schiltigheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vieux Cond√©</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.33018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wattrelos</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dormagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>D√ºsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fl√∂rsheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haag</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hatten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hohenm√∂lsen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>K√ºnzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>N√ºrnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rednitzhembach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rehburg-Loccum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rehlingen-Siersburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saarbr√ºcken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schauenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Ingbert/Oberw√ºrzbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gulbarga</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai, Maharastra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.91105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.35304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birr, Co. Offaly</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.35302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.35305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.35303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Wexford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.35306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Wexford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ebetsu, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamakura, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ube, Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.74005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.74002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.74006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.74014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.74001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.74004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.74003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trebisov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Celje</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koper</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.41004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.41003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rorschach</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88013 Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.88008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.90006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.75002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.75001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.75006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.75004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.31.75003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>July 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2014</results_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Empagliflozin 10 mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 25 mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Placebo tablets matching Empagliflozin / Sitagliptin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="P4">
          <title>Sitagliptin 100mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching Empagliflozin 25 mg
Placebo: Placebo matching Empagliflozin 10 mg
Sitagliptin 100mg: Sitagliptin once daily</description>
        </group>
        <group group_id="P5">
          <title>Empagliflozin 10 mg (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Empagliflozin 10 mg tablets once daily
Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="P6">
          <title>Empagliflozin 25 mg (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="P7">
          <title>Placebo (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Placebo tablets matching Empagliflozin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="P8">
          <title>Empagliflozin 10 mg (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg
Empagliflozin 10 mg: Empagliflozin 10 mg once daily</description>
        </group>
        <group group_id="P9">
          <title>Empagliflozin 25 mg (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="P10">
          <title>Placebo (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Placebo tablets matching Empagliflozin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="P11">
          <title>Empagliflozin 10 mg (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 10 mg tablets once daily
Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="P12">
          <title>Empagliflozin 25 mg (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="P13">
          <title>Placebo (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from trial 1245.23
Placebo tablets matching Empagliflozin
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="228"/>
                <participants group_id="P4" count="223"/>
                <participants group_id="P5" count="165"/>
                <participants group_id="P6" count="168"/>
                <participants group_id="P7" count="166"/>
                <participants group_id="P8" count="217"/>
                <participants group_id="P9" count="214"/>
                <participants group_id="P10" count="207"/>
                <participants group_id="P11" count="226"/>
                <participants group_id="P12" count="218"/>
                <participants group_id="P13" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="143"/>
                <participants group_id="P3" count="119"/>
                <participants group_id="P4" count="136"/>
                <participants group_id="P5" count="93"/>
                <participants group_id="P6" count="94"/>
                <participants group_id="P7" count="78"/>
                <participants group_id="P8" count="162"/>
                <participants group_id="P9" count="139"/>
                <participants group_id="P10" count="121"/>
                <participants group_id="P11" count="150"/>
                <participants group_id="P12" count="150"/>
                <participants group_id="P13" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="87"/>
                <participants group_id="P5" count="72"/>
                <participants group_id="P6" count="74"/>
                <participants group_id="P7" count="88"/>
                <participants group_id="P8" count="55"/>
                <participants group_id="P9" count="75"/>
                <participants group_id="P10" count="86"/>
                <participants group_id="P11" count="76"/>
                <participants group_id="P12" count="68"/>
                <participants group_id="P13" count="98"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="13"/>
                <participants group_id="P11" count="11"/>
                <participants group_id="P12" count="13"/>
                <participants group_id="P13" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>discontinued in preceding trial</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="21"/>
                <participants group_id="P11" count="17"/>
                <participants group_id="P12" count="17"/>
                <participants group_id="P13" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not continue in extension</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="54"/>
                <participants group_id="P8" count="36"/>
                <participants group_id="P9" count="44"/>
                <participants group_id="P10" count="48"/>
                <participants group_id="P11" count="45"/>
                <participants group_id="P12" count="34"/>
                <participants group_id="P13" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Empagliflozin 10 mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Empagliflozin 10 mg tablets once daily
Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 25 mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Sitagliptin
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Placebo tablets matching Empagliflozin / Sitagliptin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="B4">
          <title>Sitagliptin 100 mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching Empagliflozin 25 mg
Placebo: Placebo matching Empagliflozin 10 mg
Sitagliptin 100 mg: Sitagliptin once daily</description>
        </group>
        <group group_id="B5">
          <title>Empagliflozin 10 mg (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Empagliflozin 10 mg tablets once daily
Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="B6">
          <title>Empagliflozin 25 mg (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="B7">
          <title>Placebo (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Placebo tablets matching Empagliflozin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="B8">
          <title>Empagliflozin 10 mg (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg
Empagliflozin 10 mg: Empagliflozin 10 mg once daily</description>
        </group>
        <group group_id="B9">
          <title>Empagliflozin 25 mg (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="B10">
          <title>Placebo (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Placebo tablets matching Empagliflozin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="B11">
          <title>Empagliflozin 10 mg (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 10 mg tablets once daily
Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="B12">
          <title>Empagliflozin 25 mg (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="B13">
          <title>Placebo (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from trial 1245.23
Placebo tablets matching Empagliflozin
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="224"/>
            <count group_id="B2" value="224"/>
            <count group_id="B3" value="228"/>
            <count group_id="B4" value="223"/>
            <count group_id="B5" value="165"/>
            <count group_id="B6" value="168"/>
            <count group_id="B7" value="165"/>
            <count group_id="B8" value="217"/>
            <count group_id="B9" value="213"/>
            <count group_id="B10" value="207"/>
            <count group_id="B11" value="225"/>
            <count group_id="B12" value="216"/>
            <count group_id="B13" value="225"/>
            <count group_id="B14" value="2700"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="11.6"/>
                    <measurement group_id="B2" value="53.8" spread="11.6"/>
                    <measurement group_id="B3" value="54.9" spread="10.9"/>
                    <measurement group_id="B4" value="55.1" spread="9.9"/>
                    <measurement group_id="B5" value="54.7" spread="9.9"/>
                    <measurement group_id="B6" value="54.2" spread="8.9"/>
                    <measurement group_id="B7" value="54.6" spread="10.5"/>
                    <measurement group_id="B8" value="55.5" spread="9.9"/>
                    <measurement group_id="B9" value="55.6" spread="10.2"/>
                    <measurement group_id="B10" value="56.0" spread="9.7"/>
                    <measurement group_id="B11" value="57.0" spread="9.2"/>
                    <measurement group_id="B12" value="57.4" spread="9.3"/>
                    <measurement group_id="B13" value="56.9" spread="9.2"/>
                    <measurement group_id="B14" value="55.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="82"/>
                    <measurement group_id="B6" value="83"/>
                    <measurement group_id="B7" value="92"/>
                    <measurement group_id="B8" value="92"/>
                    <measurement group_id="B9" value="93"/>
                    <measurement group_id="B10" value="91"/>
                    <measurement group_id="B11" value="112"/>
                    <measurement group_id="B12" value="102"/>
                    <measurement group_id="B13" value="113"/>
                    <measurement group_id="B14" value="1208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="83"/>
                    <measurement group_id="B6" value="85"/>
                    <measurement group_id="B7" value="73"/>
                    <measurement group_id="B8" value="125"/>
                    <measurement group_id="B9" value="120"/>
                    <measurement group_id="B10" value="116"/>
                    <measurement group_id="B11" value="113"/>
                    <measurement group_id="B12" value="114"/>
                    <measurement group_id="B13" value="112"/>
                    <measurement group_id="B14" value="1492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment</title>
        <description>Change from baseline in HbA1c after 52 weeks</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial.
(LOCF:Last observation carried forward)</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment</title>
          <description>Change from baseline in HbA1c after 52 weeks</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial.
(LOCF:Last observation carried forward)</population>
          <units>% of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="165"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="217"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="216"/>
                <count group_id="O13" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.05"/>
                    <measurement group_id="O2" value="-0.82" spread="0.05"/>
                    <measurement group_id="O3" value="0.09" spread="0.05"/>
                    <measurement group_id="O4" value="-0.58" spread="0.05"/>
                    <measurement group_id="O5" value="-0.63" spread="0.07"/>
                    <measurement group_id="O6" value="-0.71" spread="0.07"/>
                    <measurement group_id="O7" value="-0.03" spread="0.07"/>
                    <measurement group_id="O8" value="-0.69" spread="0.05"/>
                    <measurement group_id="O9" value="-0.76" spread="0.05"/>
                    <measurement group_id="O10" value="-0.07" spread="0.05"/>
                    <measurement group_id="O11" value="-0.78" spread="0.05"/>
                    <measurement group_id="O12" value="-0.74" spread="0.05"/>
                    <measurement group_id="O13" value="-0.04" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>statistical analysis at week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>statistical analysis at week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>-0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>statistical analysis at week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>statistical analysis at week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1245</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>statistical analysis at week 52</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c (%) Changes From Baseline After 76 Weeks of Treatment</title>
        <description>Change from baseline in HbA1c (%) after 76 weeks using MMRM approach</description>
        <time_frame>Baseline and 76 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial. (OC: Observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c (%) Changes From Baseline After 76 Weeks of Treatment</title>
          <description>Change from baseline in HbA1c (%) after 76 weeks using MMRM approach</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial. (OC: Observed cases)</population>
          <units>% of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="31"/>
                <count group_id="O8" value="130"/>
                <count group_id="O9" value="118"/>
                <count group_id="O10" value="70"/>
                <count group_id="O11" value="110"/>
                <count group_id="O12" value="103"/>
                <count group_id="O13" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.07"/>
                    <measurement group_id="O2" value="-0.77" spread="0.07"/>
                    <measurement group_id="O3" value="0.13" spread="0.08"/>
                    <measurement group_id="O4" value="-0.48" spread="0.07"/>
                    <measurement group_id="O5" value="-0.67" spread="0.09"/>
                    <measurement group_id="O6" value="-0.77" spread="0.08"/>
                    <measurement group_id="O7" value="-0.05" spread="0.12"/>
                    <measurement group_id="O8" value="-0.60" spread="0.06"/>
                    <measurement group_id="O9" value="-0.76" spread="0.07"/>
                    <measurement group_id="O10" value="0.07" spread="0.08"/>
                    <measurement group_id="O11" value="-0.75" spread="0.08"/>
                    <measurement group_id="O12" value="-0.75" spread="0.08"/>
                    <measurement group_id="O13" value="0.06" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0322</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, visit, treatment as fixed effects, and visit by treatment interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment</title>
        <description>Systolic blood pressure - change from baseline after 52 weeks of treatment</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline systolic blood pressure assessment, irrespective of participation in the extension trial. (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment</title>
          <description>Systolic blood pressure - change from baseline after 52 weeks of treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline systolic blood pressure assessment, irrespective of participation in the extension trial. (LOCF)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="165"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="217"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="216"/>
                <count group_id="O13" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="0.8"/>
                    <measurement group_id="O2" value="-4.5" spread="0.8"/>
                    <measurement group_id="O3" value="-1.6" spread="0.8"/>
                    <measurement group_id="O4" value="-0.2" spread="0.8"/>
                    <measurement group_id="O5" value="-1.8" spread="0.9"/>
                    <measurement group_id="O6" value="-3.3" spread="0.9"/>
                    <measurement group_id="O7" value="0.6" spread="0.9"/>
                    <measurement group_id="O8" value="-3.6" spread="0.7"/>
                    <measurement group_id="O9" value="-5.2" spread="0.7"/>
                    <measurement group_id="O10" value="-0.7" spread="0.7"/>
                    <measurement group_id="O11" value="-3.1" spread="0.7"/>
                    <measurement group_id="O12" value="-2.7" spread="0.7"/>
                    <measurement group_id="O13" value="-0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>-2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2107</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0105</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0543</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0096</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment</title>
        <description>Change from baseline in HbA1c after 76 weeks</description>
        <time_frame>Baseline and 76 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial. (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment</title>
          <description>Change from baseline in HbA1c after 76 weeks</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial. (LOCF)</population>
          <units>% of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="165"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="217"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="216"/>
                <count group_id="O13" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.06"/>
                    <measurement group_id="O2" value="-0.76" spread="0.06"/>
                    <measurement group_id="O3" value="0.13" spread="0.06"/>
                    <measurement group_id="O4" value="-0.53" spread="0.06"/>
                    <measurement group_id="O5" value="-0.61" spread="0.07"/>
                    <measurement group_id="O6" value="-0.70" spread="0.07"/>
                    <measurement group_id="O7" value="-0.01" spread="0.07"/>
                    <measurement group_id="O8" value="-0.62" spread="0.05"/>
                    <measurement group_id="O9" value="-0.74" spread="0.05"/>
                    <measurement group_id="O10" value="-0.01" spread="0.05"/>
                    <measurement group_id="O11" value="-0.74" spread="0.06"/>
                    <measurement group_id="O12" value="-0.72" spread="0.06"/>
                    <measurement group_id="O13" value="-0.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1310</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0050</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline HbA1c as a linear covariate, baseline estimated glomerular filtration rate (eGFR), geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment</title>
        <description>Systolic blood pressure - change from baseline after 76 weeks of treatment</description>
        <time_frame>Baseline and 76 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline systolic blood pressure assessment, irrespective of participation in the extension trial -LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment</title>
          <description>Systolic blood pressure - change from baseline after 76 weeks of treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline systolic blood pressure assessment, irrespective of participation in the extension trial -LOCF</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="165"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="217"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="216"/>
                <count group_id="O13" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="0.8"/>
                    <measurement group_id="O2" value="-4.2" spread="0.8"/>
                    <measurement group_id="O3" value="-0.7" spread="0.8"/>
                    <measurement group_id="O4" value="-0.3" spread="0.8"/>
                    <measurement group_id="O5" value="-1.7" spread="0.9"/>
                    <measurement group_id="O6" value="-3.4" spread="0.9"/>
                    <measurement group_id="O7" value="0.3" spread="0.9"/>
                    <measurement group_id="O8" value="-5.2" spread="0.8"/>
                    <measurement group_id="O9" value="-4.5" spread="0.8"/>
                    <measurement group_id="O10" value="-0.8" spread="0.8"/>
                    <measurement group_id="O11" value="-3.8" spread="0.7"/>
                    <measurement group_id="O12" value="-3.7" spread="0.7"/>
                    <measurement group_id="O13" value="-1.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7241</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>-1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>-1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0987</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>-2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0213</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0288</p_value>
            <p_value_desc>Model includes baseline sys blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment</title>
        <description>Diastolic blood pressure - change from baseline after 52 weeks of treatment</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline diastolic blood pressure assessment, irrespective of participation in the extension trial -LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment</title>
          <description>Diastolic blood pressure - change from baseline after 52 weeks of treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline diastolic blood pressure assessment, irrespective of participation in the extension trial -LOCF</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="165"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="217"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="216"/>
                <count group_id="O13" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.5"/>
                    <measurement group_id="O2" value="-1.9" spread="0.5"/>
                    <measurement group_id="O3" value="-0.2" spread="0.5"/>
                    <measurement group_id="O4" value="-0.3" spread="0.5"/>
                    <measurement group_id="O5" value="-1.6" spread="0.5"/>
                    <measurement group_id="O6" value="-2.2" spread="0.5"/>
                    <measurement group_id="O7" value="0.4" spread="0.5"/>
                    <measurement group_id="O8" value="-2.2" spread="0.5"/>
                    <measurement group_id="O9" value="-2.1" spread="0.5"/>
                    <measurement group_id="O10" value="-0.4" spread="0.5"/>
                    <measurement group_id="O11" value="-1.7" spread="0.5"/>
                    <measurement group_id="O12" value="-1.6" spread="0.5"/>
                    <measurement group_id="O13" value="-1.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1058</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8259</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1660</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0212</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0076</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0170</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0236</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2523</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3494</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment</title>
        <description>Diastolic blood pressure - change from baseline after 76 weeks of treatment</description>
        <time_frame>Baseline and 76 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline diastolic blood pressure assessment, irrespective of participation in the extension trial -LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment</title>
          <description>Diastolic blood pressure - change from baseline after 76 weeks of treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline diastolic blood pressure assessment, irrespective of participation in the extension trial -LOCF</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="165"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="217"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="216"/>
                <count group_id="O13" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.5"/>
                    <measurement group_id="O2" value="-1.6" spread="0.5"/>
                    <measurement group_id="O3" value="-0.6" spread="0.5"/>
                    <measurement group_id="O4" value="-0.1" spread="0.5"/>
                    <measurement group_id="O5" value="-1.3" spread="0.5"/>
                    <measurement group_id="O6" value="-2.0" spread="0.5"/>
                    <measurement group_id="O7" value="0.2" spread="0.5"/>
                    <measurement group_id="O8" value="-2.5" spread="0.5"/>
                    <measurement group_id="O9" value="-1.9" spread="0.5"/>
                    <measurement group_id="O10" value="-0.5" spread="0.5"/>
                    <measurement group_id="O11" value="-2.6" spread="0.5"/>
                    <measurement group_id="O12" value="-2.3" spread="0.5"/>
                    <measurement group_id="O13" value="-1.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1568</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1323</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4327</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0289</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0231</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0513</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0084</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0677</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0814</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1785</p_value>
            <p_value_desc>Model includes baseline diastolic blood pressure, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight (kg) Change From Baseline After 52 Weeks of Treatment</title>
        <description>Body Weight (kg) - Change From Baseline After 52 Weeks of Treatment</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline body weight assessment, irrespective of participation in the extension trial. - LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight (kg) Change From Baseline After 52 Weeks of Treatment</title>
          <description>Body Weight (kg) - Change From Baseline After 52 Weeks of Treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline body weight assessment, irrespective of participation in the extension trial. - LOCF</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="165"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="217"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="216"/>
                <count group_id="O13" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" spread="0.19"/>
                    <measurement group_id="O2" value="-2.61" spread="0.19"/>
                    <measurement group_id="O3" value="-0.48" spread="0.19"/>
                    <measurement group_id="O4" value="0.14" spread="0.19"/>
                    <measurement group_id="O5" value="-1.50" spread="0.24"/>
                    <measurement group_id="O6" value="-1.40" spread="0.24"/>
                    <measurement group_id="O7" value="0.59" spread="0.24"/>
                    <measurement group_id="O8" value="-2.27" spread="0.19"/>
                    <measurement group_id="O9" value="-2.84" spread="0.19"/>
                    <measurement group_id="O10" value="-0.54" spread="0.20"/>
                    <measurement group_id="O11" value="-2.28" spread="0.18"/>
                    <measurement group_id="O12" value="-2.32" spread="0.19"/>
                    <measurement group_id="O13" value="-0.31" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.75</ci_lower_limit>
            <ci_upper_limit>-1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>-1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0223</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.37</ci_lower_limit>
            <ci_upper_limit>-2.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.28</ci_lower_limit>
            <ci_upper_limit>-2.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.76</ci_lower_limit>
            <ci_upper_limit>-1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>-1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>-1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.85</ci_lower_limit>
            <ci_upper_limit>-1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>-1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>-1.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight (kg) Change From Baseline After 76 Weeks of Treatment</title>
        <description>Body Weight (kg) - Change From Baseline After 76 Weeks of Treatment</description>
        <time_frame>Baseline and 76 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline body weight assessment, irrespective of participation in the extension trial -LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight (kg) Change From Baseline After 76 Weeks of Treatment</title>
          <description>Body Weight (kg) - Change From Baseline After 76 Weeks of Treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline body weight assessment, irrespective of participation in the extension trial -LOCF</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="165"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="217"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="216"/>
                <count group_id="O13" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="0.20"/>
                    <measurement group_id="O2" value="-2.45" spread="0.20"/>
                    <measurement group_id="O3" value="-0.43" spread="0.20"/>
                    <measurement group_id="O4" value="0.10" spread="0.20"/>
                    <measurement group_id="O5" value="-1.47" spread="0.26"/>
                    <measurement group_id="O6" value="-1.21" spread="0.26"/>
                    <measurement group_id="O7" value="0.50" spread="0.26"/>
                    <measurement group_id="O8" value="-2.39" spread="0.21"/>
                    <measurement group_id="O9" value="-2.65" spread="0.22"/>
                    <measurement group_id="O10" value="-0.46" spread="0.22"/>
                    <measurement group_id="O11" value="-2.44" spread="0.19"/>
                    <measurement group_id="O12" value="-2.28" spread="0.20"/>
                    <measurement group_id="O13" value="-0.63" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.35</ci_lower_limit>
            <ci_upper_limit>-1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.56</ci_lower_limit>
            <ci_upper_limit>-1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0546</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>-1.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.10</ci_lower_limit>
            <ci_upper_limit>-2.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.69</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.43</ci_lower_limit>
            <ci_upper_limit>-0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>-1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.79</ci_lower_limit>
            <ci_upper_limit>-1.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.34</ci_lower_limit>
            <ci_upper_limit>-1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline weight, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>-1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference (cm) Change From Baseline After 52 Weeks of Treatment</title>
        <description>Waist circumference (cm) - change from baseline after 52 weeks of treatment</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline waist circumference assessment, irrespective of participation in the extension trial -LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference (cm) Change From Baseline After 52 Weeks of Treatment</title>
          <description>Waist circumference (cm) - change from baseline after 52 weeks of treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline waist circumference assessment, irrespective of participation in the extension trial -LOCF</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="221"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="167"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="216"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="222"/>
                <count group_id="O12" value="215"/>
                <count group_id="O13" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.4"/>
                    <measurement group_id="O2" value="-1.7" spread="0.4"/>
                    <measurement group_id="O3" value="0.1" spread="0.4"/>
                    <measurement group_id="O4" value="0.4" spread="0.4"/>
                    <measurement group_id="O5" value="-1.5" spread="0.4"/>
                    <measurement group_id="O6" value="-1.1" spread="0.4"/>
                    <measurement group_id="O7" value="-0.1" spread="0.4"/>
                    <measurement group_id="O8" value="-1.5" spread="0.3"/>
                    <measurement group_id="O9" value="-2.0" spread="0.3"/>
                    <measurement group_id="O10" value="-0.4" spread="0.3"/>
                    <measurement group_id="O11" value="-1.5" spread="0.3"/>
                    <measurement group_id="O12" value="-1.5" spread="0.3"/>
                    <measurement group_id="O13" value="-0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5052</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0642</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0053</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference (cm) Change From Baseline After 76 Weeks of Treatment</title>
        <description>Waist circumference (cm) - change from baseline after 76 weeks of treatment</description>
        <time_frame>Baseline and 76 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline waist circumference assessment, irrespective of participation in the extension trial -LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference (cm) Change From Baseline After 76 Weeks of Treatment</title>
          <description>Waist circumference (cm) - change from baseline after 76 weeks of treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline waist circumference assessment, irrespective of participation in the extension trial -LOCF</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="221"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="167"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="216"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="222"/>
                <count group_id="O12" value="215"/>
                <count group_id="O13" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.4"/>
                    <measurement group_id="O2" value="-1.6" spread="0.4"/>
                    <measurement group_id="O3" value="0.1" spread="0.4"/>
                    <measurement group_id="O4" value="0.5" spread="0.4"/>
                    <measurement group_id="O5" value="-1.4" spread="0.4"/>
                    <measurement group_id="O6" value="-0.9" spread="0.4"/>
                    <measurement group_id="O7" value="0.0" spread="0.4"/>
                    <measurement group_id="O8" value="-1.8" spread="0.3"/>
                    <measurement group_id="O9" value="-1.3" spread="0.3"/>
                    <measurement group_id="O10" value="-0.2" spread="0.3"/>
                    <measurement group_id="O11" value="-1.6" spread="0.3"/>
                    <measurement group_id="O12" value="-1.4" spread="0.3"/>
                    <measurement group_id="O13" value="-0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5044</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1238</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>-0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0076</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0178</p_value>
            <p_value_desc>Model includes baseline waist circumference, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose Change From Baseline After 52 Weeks of Treatment</title>
        <description>Fasting plasma glucose - change from baseline after 52 weeks of treatment</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline fasting plasma glucose assessment, irrespective of participation in the extension trial -LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose Change From Baseline After 52 Weeks of Treatment</title>
          <description>Fasting plasma glucose - change from baseline after 52 weeks of treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline fasting plasma glucose assessment, irrespective of participation in the extension trial -LOCF</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="226"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="216"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="215"/>
                <count group_id="O13" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.9" spread="2.0"/>
                    <measurement group_id="O2" value="-23.9" spread="2.0"/>
                    <measurement group_id="O3" value="13.3" spread="2.0"/>
                    <measurement group_id="O4" value="-3.9" spread="2.0"/>
                    <measurement group_id="O5" value="-16.7" spread="2.8"/>
                    <measurement group_id="O6" value="-20.7" spread="2.8"/>
                    <measurement group_id="O7" value="10.3" spread="2.8"/>
                    <measurement group_id="O8" value="-16.7" spread="1.9"/>
                    <measurement group_id="O9" value="-19.7" spread="1.9"/>
                    <measurement group_id="O10" value="7.6" spread="2.0"/>
                    <measurement group_id="O11" value="-18.4" spread="2.1"/>
                    <measurement group_id="O12" value="-19.3" spread="2.1"/>
                    <measurement group_id="O13" value="9.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-32.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.8</ci_lower_limit>
            <ci_upper_limit>-26.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-37.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.8</ci_lower_limit>
            <ci_upper_limit>-31.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-17.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.9</ci_lower_limit>
            <ci_upper_limit>-11.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-15.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.6</ci_lower_limit>
            <ci_upper_limit>-9.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-19.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.5</ci_lower_limit>
            <ci_upper_limit>-14.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-27.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.0</ci_lower_limit>
            <ci_upper_limit>-19.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-31.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.9</ci_lower_limit>
            <ci_upper_limit>-23.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-24.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.7</ci_lower_limit>
            <ci_upper_limit>-18.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-27.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.7</ci_lower_limit>
            <ci_upper_limit>-21.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-27.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.6</ci_lower_limit>
            <ci_upper_limit>-22.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-28.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.5</ci_lower_limit>
            <ci_upper_limit>-22.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment</title>
        <description>Fasting plasma glucose - change from baseline after 76 weeks of treatment</description>
        <time_frame>Baseline and 76 weeks</time_frame>
        <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline fasting plasma glucose assessment, irrespective of participation in the extension trial -LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>BI 10773 Low (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O2">
            <title>BI 10773 High (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
BI 10773 tablets once daily
Placebo: Placebo matching Sitagliptin
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Placebo tablets matching BI 10773 / Sitagliptin once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100mg (Drug Naive)</title>
            <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching BI 10773 high dose
Placebo: Placebo matching BI 10773 low dose
Sitagliptin 100mg: Sitagliptin once daily</description>
          </group>
          <group group_id="O5">
            <title>BI 10773 Low (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O6">
            <title>BI 10773 High (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O7">
            <title>Placebo (Pioglitazone)</title>
            <description>Patients rolled over from trial 1245.19
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O8">
            <title>BI 10773 Low (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose
BI 10773: BI 10773 tablets once daily</description>
          </group>
          <group group_id="O9">
            <title>BI 10773 High (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O10">
            <title>Placebo (Metformin)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773 once daily
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O11">
            <title>BI 10773 Low (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
          <group group_id="O12">
            <title>BI 10773 High (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
BI 10773 tablets once daily
BI 10773: BI 10773 tablets once daily
Placebo: Placebo matching BI 10773 low dose</description>
          </group>
          <group group_id="O13">
            <title>Placebo (Metformin+Sulfonylurea)</title>
            <description>Patients rolled over from trial 1245.23
Placebo tablets matching BI 10773
Placebo: Placebo matching BI 10773 low dose
Placebo: Placebo matching BI 10773 high dose</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment</title>
          <description>Fasting plasma glucose - change from baseline after 76 weeks of treatment</description>
          <population>Full Analysis Set (FAS) which contained all randomised patients who received at least 1 dose of study drug and had a baseline fasting plasma glucose assessment, irrespective of participation in the extension trial -LOCF</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="226"/>
                <count group_id="O4" value="223"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="168"/>
                <count group_id="O7" value="165"/>
                <count group_id="O8" value="216"/>
                <count group_id="O9" value="213"/>
                <count group_id="O10" value="207"/>
                <count group_id="O11" value="225"/>
                <count group_id="O12" value="215"/>
                <count group_id="O13" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" spread="2.1"/>
                    <measurement group_id="O2" value="-20.4" spread="2.1"/>
                    <measurement group_id="O3" value="14.4" spread="2.1"/>
                    <measurement group_id="O4" value="-1.8" spread="2.1"/>
                    <measurement group_id="O5" value="-13.9" spread="2.9"/>
                    <measurement group_id="O6" value="-18.0" spread="2.9"/>
                    <measurement group_id="O7" value="9.4" spread="2.9"/>
                    <measurement group_id="O8" value="-14.5" spread="2.0"/>
                    <measurement group_id="O9" value="-20.9" spread="2.0"/>
                    <measurement group_id="O10" value="10.5" spread="2.0"/>
                    <measurement group_id="O11" value="-19.5" spread="2.2"/>
                    <measurement group_id="O12" value="-20.4" spread="2.2"/>
                    <measurement group_id="O13" value="11.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-31.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.4</ci_lower_limit>
            <ci_upper_limit>-25.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-34.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.7</ci_lower_limit>
            <ci_upper_limit>-29.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-16.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.1</ci_lower_limit>
            <ci_upper_limit>-10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-15.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.2</ci_lower_limit>
            <ci_upper_limit>-9.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-18.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.5</ci_lower_limit>
            <ci_upper_limit>-12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-23.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.4</ci_lower_limit>
            <ci_upper_limit>-15.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-27.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.4</ci_lower_limit>
            <ci_upper_limit>-19.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-25.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.5</ci_lower_limit>
            <ci_upper_limit>-19.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-31.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.9</ci_lower_limit>
            <ci_upper_limit>-25.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-31.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.0</ci_lower_limit>
            <ci_upper_limit>-24.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Model includes baseline fasting plasma glucose, baseline HbA1c as covariates, baseline eGFR, geographic region, and treatment as fixed effects.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-31.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.9</ci_lower_limit>
            <ci_upper_limit>-25.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of the informed consent until 7 days (inclusive) after last treatment</time_frame>
      <desc>For all safety analyses (except drug-related AEs), patients are assigned to the treatment group ‚Äúas treated‚Äù at inclusion (if a patient erroneously receives the wrong trial drug, the patient is analysed as per the first treatment received). For drug-related AEs, patients are assigned to the actual treatment at onset of AE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Empagliflozin 10 mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 25 mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Placebo tablets matching Empagliflozin / Sitagliptin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Sitagliptin
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="E4">
          <title>Sitagliptin 100mg (Drug Naive)</title>
          <description>Patients rolled over from trial 1245.20
Sitagliptin once daily
Placebo: Placebo matching Empagliflozin 25 mg
Placebo: Placebo matching Empagliflozin 10 mg
Sitagliptin 100mg: Sitagliptin once daily</description>
        </group>
        <group group_id="E5">
          <title>Empagliflozin 10 mg (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Empagliflozin 10 mg tablets once daily
Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="E6">
          <title>Empagliflozin 25 mg (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="E7">
          <title>Placebo (Pioglitazone)</title>
          <description>Patients rolled over from trial 1245.19
Placebo tablets matching Empagliflozin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="E8">
          <title>Empagliflozin 10 mg (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg
Empagliflozin 10 mg: Empagliflozin 10 mg once daily</description>
        </group>
        <group group_id="E9">
          <title>Empagliflozin 25 mg (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="E10">
          <title>Placebo (Metformin)</title>
          <description>Patients rolled over from trial 1245.23
Placebo tablets matching Empagliflozin once daily
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="E11">
          <title>Empagliflozin 10 mg (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 10 mg tablets once daily
Empagliflozin 10 mg: Empagliflozin 10 mg tablets once daily
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
        <group group_id="E12">
          <title>Empagliflozin 25 mg (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from trial 1245.23
Empagliflozin 25 mg tablets once daily
Empagliflozin 25 mg: Empagliflozin 25 mg tablets once daily
Placebo: Placebo matching Empagliflozin 10 mg</description>
        </group>
        <group group_id="E13">
          <title>Placebo (Metformin+Sulfonylurea)</title>
          <description>Patients rolled over from 1245.23
Placebo tablets matching Empagliflozin
Placebo: Placebo matching Empagliflozin 10 mg
Placebo: Placebo matching Empagliflozin 25 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="31" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="29" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="24" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gilbert's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Syringomyelia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Empty sella syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Amoebic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Genital infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Schistosomiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Insulin-requiring type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Osteoarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Femoroacetabular impingement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Anaplastic large cell lymphoma T- and null-cell types</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Radiculitis brachial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hypotonic urinary bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Upper airway resistance syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Photocoagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Vascular calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="116" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="110" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="96" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="107" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="122" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="113" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="106" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="146" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="147" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="142" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="28" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="33" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="33" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="39" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="36" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="29" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="24" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="36" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="34" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="21" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="24" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="18" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="21" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="56" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="25" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="59" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="24" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="26" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="40" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="53" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="46" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="16" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="17" subjects_at_risk="217"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="17" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="224"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="206"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="217"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="225"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="224"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdf@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

